Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
Zulato E, Attili I, Pavan A, Nardo G, Del Bianco P, Boscolo Bragadin A, Verza M, Pasqualini L, Pasello G, Fassan M, Calabrese F, Guarneri V, Amadori A, Conte P, Indraccolo S, Bonanno L.
Zulato E, et al.
Br J Cancer. 2020 Jul;123(1):81-91. doi: 10.1038/s41416-020-0833-7. Epub 2020 May 7.
Br J Cancer. 2020.
PMID: 32376889
Free PMC article.